Spanish Breast Cancer Research Group

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Private

Established: 1995-01-01

Employees: 101

Market Cap: -

Website: https://www.geicam.org

Clinical Trials

Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Radiation: Radiotherapy

First Posted Date: 2007-02-14

Last Posted Date: 2019-02-21

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 1

Registration Number: NCT00434941

Locations: 🇪🇸
Hospital Infanta Cristina, Badajoz, Spain
🇪🇸
Hospital Universitario de la Princesa, Madrid, Spain
🇪🇸
Hospital Clínico Universitario San Carlos, Madrid, Spain

and more 4 locations

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Exemestane
Drug: Cyclophosphamide
Drug: Goserelin
Drug: Docetaxel
Drug: Carboplatin

First Posted Date: 2007-02-07

Last Posted Date: 2023-04-03

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 189

Registration Number: NCT00432172

Locations: 🇪🇸
Onkologikoa, Donostia, Gipuzkoa, Spain
🇪🇸
Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
🇪🇸
Centro Oncológico Regional de Galicia, A Coruña, Spain

and more 9 locations

Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Liposomal Doxorubicin
Drug: Cyclophosphamide
Drug: Trastuzumab

First Posted Date: 2005-11-28

Last Posted Date: 2023-04-04

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 49

Registration Number: NCT00258960

Locations: 🇪🇸
Hospital Puerta del Mar, Cadiz, Spain
🇪🇸
Hospital Clinic i Provincial, Barcelona, Spain
🇪🇸
Hospital Juan Canalejo, La Coruña, Spain

and more 9 locations

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Vinorelbine
Drug: Capecitabine
Drug: Trastuzumab

First Posted Date: 2005-08-15

Last Posted Date: 2019-02-26

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 14

Registration Number: NCT00130507

Locations: 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain

Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions

Phase 3

Terminated

Conditions: Breast Cancer
Neoplasm Metastasis

Interventions: Drug: Zoledronic acid

First Posted Date: 2005-08-15

Last Posted Date: 2019-04-16

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 97

Registration Number: NCT00130494

Locations: 🇪🇸
Spanish Breast Cancer Research Group (GEICAM), San Sebastián de los Reyes, Madrid, Spain

Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2005-08-15

Last Posted Date: 2023-03-31

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 876

Registration Number: NCT00130533

Locations: 🇪🇸
Hospital General Universitario Morales Meseguer, Murcia, Spain
🇪🇸
Hospital Regional Universitario Carlos Haya, Málaga, Spain
🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain

and more 45 locations

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Fluorouracil
Drug: paclitaxel
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2005-08-12

Last Posted Date: 2023-03-06

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 1289

Registration Number: NCT00129922

Locations: 🇪🇸
Hospital del Mar, Barcelona, Spain
🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸
Hospital Universitario Puerto Real, Puerto Real, Cádiz, Spain

and more 61 locations

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Epirubicin
Drug: Capecitabine
Drug: Cyclophosphamide

First Posted Date: 2005-08-12

Last Posted Date: 2023-03-31

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 1384

Registration Number: NCT00129935

Locations: 🇪🇸
Hospital Arquitecto Marcide, Ferrol, A Coruña, Spain
🇪🇸
Hospital General Universitario de Elche, Elche, Alicante, Spain
🇪🇸
Hospital General Universitario de Elda, Elda, Alicante, Spain

and more 55 locations

Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Myocet
Drug: Taxotere
Drug: Herceptin

First Posted Date: 2005-08-12

Last Posted Date: 2023-03-06

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 73

Registration Number: NCT00129896

Locations: 🇪🇸
Hospital Universitario Virgen de los Lirios, Alcoy, Alicante, Spain
🇪🇸
Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸
Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain

and more 13 locations

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Fluorouracil
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Paclitaxel

First Posted Date: 2005-08-11

Last Posted Date: 2023-03-07

Lead Sponsor: Spanish Breast Cancer Research Group

Target Recruit Count: 1925

Registration Number: NCT00129389

Locations: 🇪🇸
Hospital General de Elda, Elda, Alicante, Spain
🇪🇸
Consorci Sanitari Terrassa, Terrassa, Barcelona, Spain
🇪🇸
Hospital Clínico Universitario de Salamanca, Salamanca, Spain

and more 65 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy